KRAS and neoplasm: Recently, two K‐RASG12C mutant specific inhibitors, MRTX849 and AMG510, which could lock K‐RAS in an inactive GDP‐bound state, showed promising preclinical activity in inhibiting K‐RASG12C mutant cell proliferation and xenograft tumor growth (Romero, 2020).